Omnicef and Lomotil drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Omnicef (cefdinir) and Lomotil (atropine sulfate; diphenoxylate hydrochloride). Common drug interactions include decreased appetite among females and anhedonia among males.

The phase IV clinical study analyzes what interactions people have when they take Omnicef and Lomotil. It is created by eHealthMe based on reports of 26 people who take the same drugs from the FDA, and is updated regularly.

What is Omnicef?

Omnicef has active ingredients of cefdinir. It is often used in sinusitis. eHealthMe is studying from 2,774 Omnicef users. Check the latest studies of Omnicef.

What is Lomotil?

Lomotil has active ingredients of atropine sulfate; diphenoxylate hydrochloride. It is often used in diarrhea. eHealthMe is studying from 19,184 Lomotil users. Check the latest studies of Lomotil.



On Jul, 16, 2026

26 people who take Omnicef and Lomotil together, and have interactions are studied.

Omnicef and Lomotil drug interactions.

What are the common drug interactions of Omnicef and Lomotil, by gender? *:

female:

  1. Decreased appetite
  2. Diabetic neuropathy (neuropathic disorders that are associated with diabetes mellitus)
  3. Diarrhoea haemorrhagic (bloody diarrhoea)
  4. Diverticulum (out pouching of a hollow (or a fluid-filled) structure in the body)
  5. Dry eye (lack of adequate tears)
  6. Dry mouth
  7. Dysarthria (speech disorder)
  8. Dyspnoea at rest (difficult or laboured breathing during rest)
  9. Dyspnoea paroxysmal nocturnal (respiratory distress that awakens patients from sleep)
  10. Dysuria (painful or difficult urination)

male:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Metastases to liver (cancer spreads to liver)
  4. Abortion spontaneous (naturally occurring miscarriage)
  5. Acute respiratory failure
  6. Cerebral haematoma (collection of blood in brain)
  7. Chronic kidney disease
  8. Drug ineffective
  9. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  10. Injection site pain

What are the common drug interactions of Omnicef and Lomotil, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Depression
  2. Pyrexia (fever)
  3. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  4. Anxiety
  5. Cellulitis (infection under the skin)
  6. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  7. Injury
  8. Pain in extremity
  9. Cholecystitis (infection of gallbladder)
  10. Local swelling (swelling at the site of some application of substance or injury)

20-29:

  1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  2. Emotional distress
  3. Inflammatory bowel disease
  4. Intestinal obstruction
  5. Liver abscess (pus in liver)
  6. Nausea (feeling of having an urge to vomit)
  7. Vomiting

30-39:

  1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  2. Dyspnoea (difficult or laboured respiration)
  3. Erythema (redness of the skin)
  4. Injury
  5. Pain
  6. Pain in extremity
  7. Peripheral swelling
  8. Pulmonary embolism (blockage of the main artery of the lung)
  9. Thrombophlebitis superficial (swelling (inflammation) of a superficial vein caused by a blood clot)

40-49:

  1. Metastases to liver (cancer spreads to liver)
  2. Chronic kidney disease
  3. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  4. Injection site haemorrhage (bleeding from injection site)
  5. Nephrogenic anaemia (anaemia due to kidney disease)
  6. Renal failure (kidney dysfunction)
  7. Renal tubular necrosis (death of kidney tubules)

50-59:

  1. Cytomegalovirus viraemia (cytomegalo virus in blood stream)
  2. Diarrhoea haemorrhagic (bloody diarrhoea)
  3. Dyspnoea at rest (difficult or laboured breathing during rest)
  4. Gastric polyps (abnormal growth of stomach tissue projecting from a mucous membrane)
  5. Hepatic steatosis (fatty liver disease)
  6. Hypoglycaemia (deficiency of glucose in the bloodstream)
  7. Hypokalaemia (low potassium)
  8. Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood)
  9. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
  10. Klebsiella bacteraemia (klebsiella bacteria in blood after infection to lungs)

60+:

  1. Arthralgia (joint pain)
  2. Atelectasis (partial or complete collapse of the lung)
  3. Abasia (inability to walk)
  4. Abdominal discomfort
  5. Abdominal pain
  6. Abdominal pain upper
  7. Adenomatous polyposis coli ((fap) is an inherited condition in which numerous polyps form mainly in the epithelium of the large intestine)
  8. Alanine aminotransferase increased
  9. Anaemia (lack of blood)
  10. Antiphospholipid antibodies positive

What are the existing conditions these people have? *

  1. Pain: 6 people, 23.08%
  2. Rectal Cancer (cancer of rectum): 5 people, 19.23%
  3. Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 4 people, 15.38%
  4. Stress And Anxiety: 3 people, 11.54%
  5. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 11.54%
  6. Premenstrual Syndrome: 2 people, 7.69%
  7. Nausea (feeling of having an urge to vomit): 2 people, 7.69%
  8. Menstruation Irregular: 2 people, 7.69%
  9. Dysmenorrhea (painful menstruation): 2 people, 7.69%
  10. Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 2 people, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Omnicef and Lomotil?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Omnicef and Lomotil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Omnicef:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Lomotil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Omnicef and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Lomotil and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on cefdinir and atropine sulfate; diphenoxylate hydrochloride (the active ingredients of Omnicef and Lomotil, respectively), and Omnicef and Lomotil (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: